News
KPTI
3.180
+1.60%
0.050
Morgan Stanley Maintains Equal-Weight on Karyopharm Therapeutics, Lowers Price Target to $5
Benzinga · 21h ago
KPTI, VRNA and SGH are among after hour movers
Seeking Alpha · 01/20 21:58
Analyst Ratings for Karyopharm Therapeutics
Benzinga · 01/19 17:00
Karyopharm gains as Piper issues bullish remarks citing cancer drug
Seeking Alpha · 01/19 13:43
Piper Sandler Initiates Coverage On Karyopharm Therapeutics with Overweight Rating, Announces Price Target of $8
Benzinga · 01/19 10:10
Piper Sandler Starts Karyopharm Therapeutics at Overweight With $8 Price Target
Piper Sandler Starts Karyopharm Therapeutics at Overweight With $8 Price Target
MT Newswires · 01/19 07:24
RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)
TipRanks · 01/17 01:46
National Instruments, Virgin Galactic And Other Big Stocks Moving Higher On Friday
Benzinga · 01/13 15:53
--RBC Cuts Price Target on Karyopharm Therapeutics to $7 From $9, Maintains Outperform Rating
--RBC Cuts Price Target on Karyopharm Therapeutics to $7 From $9, Maintains Outperform Rating
MT Newswires · 01/13 08:07
Karyopharm Therapeutics (KPTI) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- Slideshow
Seeking Alpha · 01/12 16:30
Robert W. Baird Remains a Buy on Karyopharm Therapeutics (KPTI)
TipRanks · 01/12 05:25
SVB Securities Keeps Their Hold Rating on Karyopharm Therapeutics (KPTI)
TipRanks · 01/10 12:25
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI), Tenaya Therapeutics (TNYA) and OrthoPediatrics (KIDS)
TipRanks · 01/10 11:20
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $16
Benzinga · 01/10 11:09
HC Wainwright Adjusts Price Target on Karyopharm Therapeutics to $16 From $18, Maintains Buy Rating
HC Wainwright Adjusts Price Target on Karyopharm Therapeutics to $16 From $18, Maintains Buy Rating
MT Newswires · 01/10 09:58
SVB Leerink Maintains Market Perform on Karyopharm Therapeutics, Lowers Price Target to $5
Benzinga · 01/10 09:30
SVB Securities Adjusts Price Target on Karyopharm Therapeutics to $5 From $6, Maintains Market Perform Rating
SVB Securities Adjusts Price Target on Karyopharm Therapeutics to $5 From $6, Maintains Market Perform Rating
MT Newswires · 01/10 09:16
Wedbush Trims Karyopharm Therapeutics' Price Target to $6 From $7, Keeps Neutral Rating
Wedbush Trims Karyopharm Therapeutics' Price Target to $6 From $7, Keeps Neutral Rating
MT Newswires · 01/10 07:54
BRIEF-Karyopharm Announces Preliminary Unaudited Fourth Quarter And Full Year 2022 Revenue And Outlines 2023 Objectives
Reuters · 01/09 13:40
More
Webull provides a variety of real-time KPTI stock news. You can receive the latest news about Karyopharm Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe and the United Kingdom, in combination with dexamethasone to treat adult patients with multiple myeloma.